前列腺癌术后不同分割模式放射治疗急性不良反应初步研究

doi:10.3760/cma.j.issn.1004-4221.2018.07.008

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To compare the toxicity between different dose fractionation regimens in postoperative radiotherapy for prostate cancer. Methods Patients with prostate cancer who received postoperative radiotherapy with moderate hypo-fractionation (62.75 Gy in 25 fractions, 2.51 Gy per fraction) or conventional fractionation (72 Gy in 36 fractions, 2 Gy per fractions) in our hospital from 2011 to 2017 were enrolled as subjects. All patients received intensity-modulated radiotherapy and daily cone-beam computed tomography image-guided radiotherapy. According to the propensity score matching (PSM) method, 35 patients treated with moderately hypo-fractionated radiotherapy were matched to 35 patients treated with conventionally fractionated radiotherapy based on age, irradiated volume, hormonal therapy, interval between surgery and radiotherapy, and comorbidities (diabetes and hypertension). Toxicity was evaluated according to Radiation Therapy Oncology Group criteria. Comparison was made by the Fisher′s exact probability test. Results One hundred and thirteen patients, consisting of forty-one in moderate hypo-fractionation group and seventy-two in conventional fractionation group, were enrolled as subjects. The median follow-up time in the two groups was 5.6 and 45.0 months, respectively. There were no significant differences in incidence rates of grade 2 acute gastrointestinal (GI) or genitourinary (GU) toxicity between the two groups (7% vs. 7%, P=1.000;15% vs. 17%, P=0.847). After PSM, there were still no significant differences in incidence rates of grade 2 acute GI or GU toxicity between the two groups (9% vs. 11%, P=0.814;14% vs. 11%, P=0.670). None of patients reported≥grade 3 GI or GU toxicity. Conclusions Preliminary results show that moderate hypo-fractionation, compared with conventional fractionation, does not increase the risk of acute GI or GU toxicity in patients undergoing postoperative radiotherapy for prostate cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Qin Shangbin
	Gao Xianshu
	Li Hongzhen
	Gu Xiaoying
	Li Xiaoying
	Qi Xin
	Ren Xueying

Key words： Prostate neoplasms/postoperative radiotherapy Radiotherapy,moderately hypo-fractionated Radiotherapy,conventionally fractionated

Received: 16 January 2018

Fund:Specific Project of Clinical Trials of Beijing Municipal Science and Technology Commission (Z141107002514160)

Corresponding Authors: Xianshu Gao,Email:doctorgaoxs@126.com.

Cite this article:

Qin Shangbin,Gao Xianshu,Li Hongzhen et al. A preliminary toxicity study of different dose fractionation regimens in postoperative radiotherapy for prostate cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(7): 665-668.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.07.008 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I7/665

[1] Arcangeli S,Strigari L,Gomellini S,et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer[J].Int J Radiat Oncol Biol Phys,2012,84(5):1172-1178.DOI:10.1016/j.ijrobp.2012.02.049.
[2] Pollack A,Walker G,Horwitz EM,et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer[J].J Clin Oncol,2013,31(31):3860-3868.DOI:10.1200/JCO.2013.51.1972.
[3] Dearnaley D,Syndikus I,Mossop H,et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer:5-year outcomes of the randomised,non-inferiority,phase 3 CHHiP trial[J].Lancet Oncol,2016,17(8):1047-1060.DOI:10.1016/S1470-2045(16)30102-4.
[4] Mohler JL,Kantoff PW,Armstrong AJ,et al. Prostate cancer,version 2.2014[J].J Natl Compr Canc Netw,2014,12(5):686-718.
[5] National Comprehensive Cancer N.NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer[J].Verson 2.2017,https://www.nccn.org/professionals/physician_gls/default.aspx-prostate.
[6] Lewis SL,Patel P,Song H,et al. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer[J].Int J Radiat Oncol Biol Phys,2016,94(3):605-611.DOI:10.1016/j.ijrobp.2015.11.025.
[7] Wong GW,Palazzi-Churas KL,Jarrard DF,et al. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy[J].Int J Radiat Oncol Biol Phys,2008,70(2):449-455.DOI:10.1016/j.ijrobp.2007.06.042.
[8] Gladwish A,Loblaw A,Cheung P,et al. Accelerated hypofractioned postoperative radiotherapy for prostate cancer:a prospective phase Ⅰ/Ⅱ study[J].Clin Oncol (R Coll Radiol),2015,27(3):145-152.DOI:10.1016/j.clon.2014.12.003.
[9] Massaccesi M,Cilla S,Deodato F,et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy:preliminary results of a phase Ⅱ trial[J].Anticancer Res,2013,33(6):2785-2789.
[10] Macchia G,Siepe G,Capocaccia I,et al. Hypofractionated Postoperative IMRT in Prostate Carcinoma:A Phase Ⅰ/Ⅱ Study[J].Anticancer Res,2017,37(10):5821-5828.DOI:10.21873/anticanres.12025.
[11] Cozzarini C,Fiorino C,Deantoni C,et al. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy:a single-institution analysis of 1176 patients[J].Eur Urol,2014,66(6):1024-1030.DOI:10.1016/j.eururo.2014.06.012.
[12] Kruser TJ,Jarrard DF,Graf AK,et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence[J].Cancer,2011,117(12):2629-2636.DOI:10.1002/cncr.25824.
[13] Michalski JM,Lawton C,El Naqa I,et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer[J].Int J Radiat Oncol Biol Phys,2010,76(2):361-368.DOI:10.1016/j.ijrobp.2009.02.006.
[14] D′souza WD,Thames HD.Is the alpha/beta ratio for prostate cancer low?[J].Int J Radiat Oncol Biol Phys,2001,51(1):1-3.
[15] Brenner DJ,Martinez AA,Edmundson GK,et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio),similar to late-responding normal tissue[J].Int J Radiat Oncol Biol Phys,2002,52(1):6-13.
[16] Fersino S,Tebano U,Mazzola R,et al. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT):a mono-institutional report on feasibility and acute toxicity[J].Clin Genitourin Cancer,2017,15(4):e667-e673.DOI:10.1016/j.clgc.2017.01.025.